https://www.medscape.com/viewarticle/977812
A US neuroscientist claims that some of the studies of the experimental agent, Simufilam (Cassava Sciences), a drug that targets amyloid beta (Aβ) in Alzheimer's disease (AD), are flawed, and, as a result, has taken his concerns to the National Institutes of Health (NIH).
Matthew Schrag, MD, PhD, department of neurology, Vanderbilt University Medical Center, Nashville, Tennessee, uncovered what he calls inconsistencies in major studies examining the drug.
In a whistleblower report to the NIH about the drug, Schrag claims that several prominent investigators altered images and reused them over years to support the hypothesis that buildup of amyloid in the brain causes AD. The NIH has funded research into Aβ as a potential cause of AD to the tune of millions of dollars for years.
A US neuroscientist claims that some of the studies of the experimental agent, Simufilam (Cassava Sciences), a drug that targets amyloid beta (Aβ) in Alzheimer's disease (AD), are flawed, and, as a result, has taken his concerns to the National Institutes of Health (NIH).
Matthew Schrag, MD, PhD, department of neurology, Vanderbilt University Medical Center, Nashville, Tennessee, uncovered what he calls inconsistencies in major studies examining the drug.
In a whistleblower report to the NIH about the drug, Schrag claims that several prominent investigators altered images and reused them over years to support the hypothesis that buildup of amyloid in the brain causes AD. The NIH has funded research into Aβ as a potential cause of AD to the tune of millions of dollars for years.